Phase I Study of INC280 plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer.
Sponsor: University of California Davis
Location(s): United States
This phase I trial studies the side effects and best dose of c-Met inhibitor INCB028060 and erlotinib hydrochloride when given together in treating patients with previously treated non-small cell lung cancer. C-Met inhibitor INCB028060 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.